Cargando…
Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization
To report a patient with juxtapapillary choroidal osteoma (CO) with serous retinal detachment (SRD) not associated with choroidal neovascularization (CNV) who was successfully treated with a single intravitreal injection of bevacizumab. A 20-year-old woman presented with decreased vision in her righ...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795400/ https://www.ncbi.nlm.nih.gov/pubmed/27051495 http://dx.doi.org/10.4103/2008-322X.176905 |
_version_ | 1782421604207165440 |
---|---|
author | Najafabadi, Farhad Fazel Hendimarjan, Seyyed Moien Zarrin, Yasaman Najafabadi, Mohammadreza Fazel |
author_facet | Najafabadi, Farhad Fazel Hendimarjan, Seyyed Moien Zarrin, Yasaman Najafabadi, Mohammadreza Fazel |
author_sort | Najafabadi, Farhad Fazel |
collection | PubMed |
description | To report a patient with juxtapapillary choroidal osteoma (CO) with serous retinal detachment (SRD) not associated with choroidal neovascularization (CNV) who was successfully treated with a single intravitreal injection of bevacizumab. A 20-year-old woman presented with decreased vision in her right eye. Ultrasonography, fundus autofluorescence, fluorescein angiography (FA) and optical coherence tomography (OCT) were performed. She was diagnosed with juxtapapillary CO with SRD in the absence of CNV. The treatment involved a single intravitreal injection of bevacizumab. Visual acuity (VA) was 20/100 pre-injection which was dramatically improved to 20/20 one week after the injection without any additional treatment. Fundus examination and OCT one week after the injection revealed complete absorption of the subretinal fluid (SRF) in the macula. Eighteen months after the injection, vision remained stable and she did not show re-accumulation of SRF in her right eye. Intravitreal injection of bevacizumab may be effective in managing CO associated with SRF without CNV. |
format | Online Article Text |
id | pubmed-4795400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-47954002016-04-05 Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization Najafabadi, Farhad Fazel Hendimarjan, Seyyed Moien Zarrin, Yasaman Najafabadi, Mohammadreza Fazel J Ophthalmic Vis Res Case Report To report a patient with juxtapapillary choroidal osteoma (CO) with serous retinal detachment (SRD) not associated with choroidal neovascularization (CNV) who was successfully treated with a single intravitreal injection of bevacizumab. A 20-year-old woman presented with decreased vision in her right eye. Ultrasonography, fundus autofluorescence, fluorescein angiography (FA) and optical coherence tomography (OCT) were performed. She was diagnosed with juxtapapillary CO with SRD in the absence of CNV. The treatment involved a single intravitreal injection of bevacizumab. Visual acuity (VA) was 20/100 pre-injection which was dramatically improved to 20/20 one week after the injection without any additional treatment. Fundus examination and OCT one week after the injection revealed complete absorption of the subretinal fluid (SRF) in the macula. Eighteen months after the injection, vision remained stable and she did not show re-accumulation of SRF in her right eye. Intravitreal injection of bevacizumab may be effective in managing CO associated with SRF without CNV. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4795400/ /pubmed/27051495 http://dx.doi.org/10.4103/2008-322X.176905 Text en Copyright: © Journal of Ophthalmic and Vision Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Case Report Najafabadi, Farhad Fazel Hendimarjan, Seyyed Moien Zarrin, Yasaman Najafabadi, Mohammadreza Fazel Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization |
title | Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization |
title_full | Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization |
title_fullStr | Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization |
title_full_unstemmed | Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization |
title_short | Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization |
title_sort | intravitreal bevacizumab for management of choroidal osteoma without choroidal neovascularization |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795400/ https://www.ncbi.nlm.nih.gov/pubmed/27051495 http://dx.doi.org/10.4103/2008-322X.176905 |
work_keys_str_mv | AT najafabadifarhadfazel intravitrealbevacizumabformanagementofchoroidalosteomawithoutchoroidalneovascularization AT hendimarjanseyyedmoien intravitrealbevacizumabformanagementofchoroidalosteomawithoutchoroidalneovascularization AT zarrinyasaman intravitrealbevacizumabformanagementofchoroidalosteomawithoutchoroidalneovascularization AT najafabadimohammadrezafazel intravitrealbevacizumabformanagementofchoroidalosteomawithoutchoroidalneovascularization |